OTCM
BIESF
, Last price
USD
Name
Biotest AG
Chart & performance
P/E
—
P/S
—
EPS
1.33
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
11.62%
Div Yld LY
—
Div Yld TTM
—
Revenues
726m
+6.08%
Net income
26m
-79.21%
CFO
61m
P
Dividend
Jul 22, 20260.04552697 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Biotest AG is a German biopharmaceutical company focused on the global development, manufacturing, and commercialization of biological medications. The firm organizes its activities into the Therapy, Plasma & Services, and Other segments. Its product portfolio addresses critical needs in hematology, clinical immunology, and intensive care medicine. Among its offerings are treatments for hemophilia A (such as Haemoctin and Vihuma) and hemophilia B (like Haemonine), covering both acute care and prevention. Biotest also provides therapies for various viral infections, including cytomegalovirus (Cytotect CP), hepatitis B (Fovepta, Hepatect, Zutectra), and varicella zoster (Varitect). Additionally, its products, such as Intratect and IgG Next Generation, are utilized for primary and secondary immune deficiencies, autoimmune disorders, and certain neurological conditions. The company further supplies solutions to manage circulating blood volume (Albiomin, Biseko), address clotting factor deficiencies (Cofact, Fibrinogen), and combat serious infections like community-acquired pneumonia and COVID-19 (Trimodulin), as well as general bacterial infections (Pentaglobin). Established in 1946 as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. Headquartered in Dreieich, Germany, Biotest Aktiengesellschaft has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.
Related entities
Subsidiaries
Biotest Austria GmbH
Key people
Chairman of the Supervisory Board · since 2017
Ileana Carlisle
Biotest Pharmaceuticals Corporation, USA
Hermann Keuper
Senior Vice President - Manufacturing · since 2018
Oliver Hein
Corporate Risk and Compliance Officer
Martin Moeller
Group Finance and Treasury Officer
Enrico D'Aiuto
Global Sales Officer
Christina Erb
Head of Corporate Human Resources · since 2018
Monika Buttkereit
Head of Investor Relations
Katrin Bernoester
Head of Project Management · since 2019
Stephan Fleck
Corporate Controlling Officer
Robert Lefebvre
Global Strategy Officer
Michael Moritz
Materials & Facility Management, Biotest Next Level Officer
Dirk Neumueller
Corporate Communication Officer
Martin Reinecke
Plasma Alliances and Protein Supply Officer
Joerg Schuettrumpf
Global Research Officer
Peter Seith
Quality Operations Officer
Frank Velte
Commercial Operations Germany Officer
Cathrin Schleussner
Deputy Chairperson of the Supervisory Board · since 2004
Tan Yang
Deputy Chairman of the Supervisory Board · since 2018
Kerstin Birkhahn
Member of the Supervisory Board, Employee Representative · since 2010
Headquarters & legal address
Landsteinerstraße 5
Dreieich, HE 63303
DE
Dreieich, HE 63303
DE
Previous name
Biotest Aktiengesellschaft
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||